Mednax to Present at Upcoming Investor Conferences
February 22 2021 - 6:45AM
Business Wire
Mednax, Inc. (NYSE: MD) today announced that it is scheduled to
make presentations at two upcoming investor conferences.
The Company will present on Thursday, February 25, 2021 at 2:25
p.m. ET to investors attending Citi’s 2021 Healthcare Services,
Medtech, Tools, & HCIT Virtual Conference.
Mednax will also present on Monday, March 1, 2021 at 10:00 a.m.
ET to investors attending the J.P. Morgan Global High Yield &
Leveraged Finance Conference, taking place virtually.
The presentations will be broadcast through live audio
webcasts.
ABOUT MEDNAX Mednax, Inc. is a national medical group
comprised of the nation’s leading providers of physician services.
Physicians and advanced practitioners practicing as part of Mednax
are reshaping the delivery of care within their specialties and
subspecialties, using evidence-based tools, continuous quality
initiatives, clinical research and telehealth programs to enhance
patient outcomes and provide high-quality, cost-effective care. The
Company was founded in 1979, and today, through its affiliated
professional entities, Mednax provides services through a network
of more than 2,300 physicians in 39 states and Puerto Rico.
Additional information is available at www.mednax.com.
Certain statements and information in this press release may be
deemed to contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may include, but are not limited to,
statements relating to the Company’s objectives, plans and
strategies, and all statements, other than statements of historical
facts, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology
such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,”
“plan,” “will,” “expect,” “estimate,” “project,” “positioned,”
“strategy” and similar expressions, and are based on assumptions
and assessments made by the Company’s management in light of their
experience and their perception of historical trends, current
conditions, expected future developments and other factors they
believe to be appropriate. Any forward-looking statements in this
press release are made as of the date hereof, and the Company
undertakes no duty to update or revise any such statements, whether
as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Important factors that
could cause actual results, developments, and business decisions to
differ materially from forward-looking statements are described in
the Company’s most recent Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q, including the sections entitled
“Risk Factors”, as well the Company’s current reports on Form 8-K,
filed with the Securities and Exchange Commission, and include the
impact of the COVID-19 pandemic on the Company and its financial
condition and results of operations; the effects of economic
conditions on the Company’s business; the effects of the Affordable
Care Act and potential changes thereto or a repeal thereof; the
Company’s relationships with government-sponsored or funded
healthcare programs, including Medicare and Medicaid, and with
managed care organizations and commercial health insurance payors;
the Company’s ability to comply with the terms of its debt
financing arrangements; the impact of the divestiture of the
Company’s anesthesiology and radiology medical groups; the impact
of management transitions; the timing and contribution of future
acquisitions; the effects of share repurchases; and the effects of
the Company’s transformation initiatives, including its
reorientation on, and growth strategy for, its pediatrics and
obstetrics business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210222005134/en/
Charles Lynch Senior Vice President, Finance and Strategy
954-384-0175 ext. 5692 charles_lynch@mednax.com
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jul 2023 to Jul 2024